New Mexico Company Secures Funding for Sandia Medical Isotope Concept

Agency: 
Dept. of Energy

Researcher John Hall stands near Sandia National Laboratories’ annular core research reactor, where scientists discovered a way to make medical isotopes. The concept was licensed to Eden Radioisotopes, LLC. The effort recently earned an award from the Federal Laboratory Consortium for Technology Transfer. (Photo credit: Randy Montoya)

A New Mexico company secured funding this year and located 240 acres of land in the southeastern corner of the state to build a small reactor that will exclusively produce medical isotopes. The concept was developed and licensed by Sandia National Laboratories to help establish a stable domestic supply of medical isotopes, which are made with low-enriched uranium and help diagnose a number of diseases.

Adjustments to the license made earlier this year by Sandia helped Eden Radioisotopes, LLC secure funding. Eden’s chief operations officer, Chris Wagner, said he expects to break ground on the facility once all other licensing and agreements have been reached.

This effort earned a regional Excellence in Technology Transfer Award from the Federal Laboratory Consortium for Technology Transfer (FLC), an association that recognizes industry and federal laboratories for outstanding work to develop and commercialize innovative technologies. Sandia won three additional FLC awards in other categories.

Medical isotopes used in 40 million procedures each year

Medical isotopes are used around the globe in imaging procedures that diagnose heart disease, cancer and other life-threatening conditions. The isotopes are injected into patients and emit gamma rays that can be tracked in the body, allowing physicians to create images of the spread of a disease. They also decay quickly so patients are exposed to little radiation.

Building the reactor is important because there are a limited number in the world that primarily produce molybdenum-99, or moly-99, which decays to technetium-99m, a short-lived isotope that can be used to make individual patient doses, said Wagner. Some of those reactors have unplanned outages, which cause shortages and price spikes.

Sandia’s concept to produce moly-99 with a small, 2-megawatt reactor requires less maintenance than larger reactors. The technology, which uses low-enriched uranium, could produce a reliable domestic supply of moly-99 without the use of high-enriched uranium. Eden was able to demonstrate that it had a funding plan and the experience to obtain an exclusive license for the technology.

“This has been a stellar example of transferring Sandia technology,” said Sandia business development specialist Bob Westervelt, who worked on licensing the concept. “The team that worked on this from Sandia was really committed to making this work, and Eden is making it possible for the technology to move forward. Everyone involved put in a lot of effort over many years to make this a success.”

The isotope is used for 40 million nuclear medicine diagnostic procedures each year, Wagner said. In the U.S. alone, the isotope is used for more than 40,000 medical diagnostic procedures each day, according to Sandia senior manager Matt Burger.

The purpose for producing the isotopes, and the dedication to this issue, is deeper than science and solving a problem, according to Wagner.

“This type of technology has the ability to affect millions of patients worldwide,” Wagner said. “I think what continuously drives us is that unless someone solves the supply issue, a lot of patients will be adversely impacted. At the end of the day, a lot of people will benefit, but they won’t know our names. It’s that internal satisfaction of making a difference that drives us.”

Sandia awarded for alloy, catalyst, and zero-emissions vessel research

In addition to this effort with Eden, the FLC recognized three other projects involving the labs in the Mid-Continent and Far West regions.

  • One partnership earned a Notable Technology Development Award for a breakthrough using detergent to make uniform powder catalysts that outperform commercial varieties used to kick-start chemical reactions. The catalytic compounds could be used in many applications, including environmental clean-up and cancer treatment.
  • Sandia researchers engineered the world’s most wear-resistant alloy, which has gained tech transfer interest from companies in several sectors. This technology earned the lab a Notable Technology Development Award. The alloy is 100 times more durable than high-strength steel and could make electronics of all sizes and across many industries more cost-effective, long-lasting and dependable.
  • Sandia received an Outstanding Partnership Award for research on a zero-emissions research vessel. A Sandia report showed it is technically and economically feasible to build a vessel that meets marine regulations and does not pollute the air or ocean.

“We are proud to celebrate and recognize our industry partnerships, technology and technology transfer efforts that support Sandia’s missions,” said Jackie Kerby Moore, Sandia’s manager of Technology and Economic Development and the labs’ FLC representative. “These technologies are being developed and transferred to the private sector and will create many business opportunities.”

Sandia winners were recognized at a recent awards ceremony at the FLC Far West/Mid-Continent regional meeting in Livermore, California.

To view the original news article, visit https://share-ng.sandia.gov/news/resources/news_releases/medical_isotope/.

Category: 
T2 News
Region: 
Mid-Continent